Argenx
ARGX
#532
Rank
A$59.48 B
Marketcap
$925.04
Share price
-5.92%
Change (1 day)
57.42%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): A$0.12 Billion

According to Argenx 's latest financial reports the company's current earnings are A$2.19 Billion. , an increase over its 2023 earnings that were of -A$0.51 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 A$0.14 B-127.97%
2023 -A$0.51 Billion-58.25%
2022 -A$1.22 Billion
2019 -A$0.34 Billion124.95%
2018 -A$0.15 Billion132.04%
2017 -A$63.56 Million54.86%
2016 -A$41.04 Million33%
2015 -A$30.86 Million13.63%
2014 -A$27.16 Million46.25%
2013 -A$18.57 Million